Pfizer: raises annual target ranges
(CercleFinance.com) - On its quarterly earnings call, Pfizer announced an increase in its target ranges for FY 2024, now anticipating adjusted EPS of $2.
75 to $2.95 and revenues of $61bn to $64bn.
For Q3 2024, the pharmaceutical giant posted adjusted EPS of $1.06, compared with -$0.17 a year earlier, on revenues that are up 31% to $17.7bn (+32% on an operating basis, including +14% excluding Covid-19 products).
In addition, Pfizer says it is on track to achieve at least $5.5bn in net cost savings, as part of its previously announced program, including at least $4bn by the end of 2024, and the remainder by the end of 2027.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
75 to $2.95 and revenues of $61bn to $64bn.
For Q3 2024, the pharmaceutical giant posted adjusted EPS of $1.06, compared with -$0.17 a year earlier, on revenues that are up 31% to $17.7bn (+32% on an operating basis, including +14% excluding Covid-19 products).
In addition, Pfizer says it is on track to achieve at least $5.5bn in net cost savings, as part of its previously announced program, including at least $4bn by the end of 2024, and the remainder by the end of 2027.
Copyright (c) 2024 CercleFinance.com. All rights reserved.